About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome

Published:

07 February 2020

Citation:

US Cardiology Review 2019;13(2):74–82.

Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure

Published:

07 February 2020

Citation:

US Cardiology Review 2019;13(2):83–7.

Foreword

Citation:

US Cardiology Review 2018;12(2):76.

A Message From the Outgoing Editor-in-Chief

Citation:

US Cardiology Review 2018;12(2):77.